HOME >> MEDICINE >> NEWS
Light-weight heparin has heavy-weight results in heart attack treatment

DALLAS, Heart attack patients treated with the blood-thinner enoxaparin a low molecular weight heparin plus a clot dissolver were significantly less likely to die or have repeat heart attacks within 30 days compared to patients who received unfractionated heparin (UFH), according to a Rapid Track article in todays Circulation: Journal of the American Heart Association.

Patients in the study had what are known as ST-segment elevation myocardial infarctions, which are the most severe type of heart attack. We have very encouraging data but the evidence is not yet sufficient to say that enoxaparin should be standard treatment for severe heart attacks, says Elliott Antman, M.D., associate professor of medicine at Harvard Medical School and director of the coronary care unit of Brigham and Womens Hospital in Boston. However, the data suggest we should pursue a larger clinical trial.

Enoxaparin previously has been shown to be superior to unfractionated heparin (another blood thinner) for patients with milder heart attacks (non-ST segment elevation). It can be given as a simple injection, rather than the continuous infusion required with UFH, and it does not require frequent testing of the patients blood clotting status.

The researchers report their findings from the ENTIRE-TIMI 23 study. This international study involved 483 patients who presented with severe heart attacks at hospitals in the United States and Europe. Participants were randomly assigned either standard reperfusion with a full dose of the clot-dissolving drug tenecteplase (TNK) or combination therapy with abciximab and a half dose of TNK and either unfractionated heparin (UFH) or enoxaparin. Abciximab is a drug that helps keep blood platelets from sticking together to form clots.

The study was designed to evaluate enoxaparin as adjunctive treatment with various forms of reperfusion therapies (TNK, abciximab). To evaluate reperfusion (blood flow) researchers used the TIMI
'"/>

Contact: Carole Bullock
carole.bullock@heart.org
214-706-1279
American Heart Association
4-Mar-2002


Page: 1 2

Related medicine news :

1. The protective effects of heparin in preventing miscarriages in lupus patients
2. Newer formulation of heparin improves outcomes for suspected heart attack patients
3. New studies show mixed results on epilepsy drugs and birth defects
4. Study of obese diabetics explains why low-carb diets produce fast results
5. Sharing clinical trial results with participants may be beneficial
6. Emergency clopidogrel could save thousands of lives46,000-patient heart attack trial results
7. Similar results found in both older and younger patients undergoing weight-loss surgery
8. OHSU researcher says FDA could broaden access to results of clinical drug trials
9. Kinder, gentler procedure gives superior results for stem cell transplants
10. Good results with only one egg in in-vitro fertilization
11. Holiday feasting could sabotage liposuction results

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) premiered its ... from high school and college students who have participated in the program every summer. ... YFI is now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to learn ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest ... in two southeastern states. Ingredients in HeartBoost, an over the counter heart healthy ...
(Date:3/29/2017)... ... March 29, 2017 , ... Dr. Angela Cotey, a ... treatment and accepting new pediatric patients, with or without a referral. Dr. Cotey knows ... a better orthodontic outcome and experience. When patients receive early treatment, they may achieve ...
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , a premium ... finalization of the company’s executive management team with prominent executives from both inside and ... Wellness’ Chief Operating Officer, Ted Dumbauld , who has more than twenty years ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of the ... is touted to be the next revolution in our fight against this complex disease. ... form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 29, 2017  Novartis announced today that the ... the company,s Biologics License Application (BLA) filing and ... chimeric antigen receptor T cell (CAR-T) therapy, in ... patients with B-cell acute lymphoblastic leukemia (ALL). This ... a CAR-T. The priority review designation is expected ...
(Date:3/29/2017)... 29, 2017 Research and Markets has ... 2014 - 2025" report to their offering. ... The global ... million by 2025. Increasing geriatric population prone to orthopedic diseases ... navigation systems over the forecast period. Osteoarthritis and osteoporosis are ...
(Date:3/29/2017)... WALNUT CREEK, Calif. , Mar 29, 2017 ... tissue-sparing, cervical-fusion technology, announced the addition of two ... Scott Lynch has joined the company to ... is assuming International leadership.  Together, Mr. Lynch and ... industry experience.  Mr. Lynch joins ...
Breaking Medicine Technology:
Cached News: